C Bokemeyer

Summary

Country: Germany

Publications

  1. pmc Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Haematology Oncology, University of Tuebingen Medical Center, Germany
    Br J Cancer 87:729-32. 2002
  2. pmc Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
    S Koch
    Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, , , Tuebingen 72076, Germany
    Br J Cancer 89:2133-9. 2003
  3. pmc Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen Medical Center, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Br J Cancer 86:506-11. 2002
  4. ncbi Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy
    C Bokemeyer
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 25:32-9. 2002
  5. ncbi Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis
    Carsten Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    J Clin Oncol 20:1864-73. 2002
  6. ncbi [Chemotherapy of advanced colorectal carcinoma: treatment options for elderly patients]
    C Bokemeyer
    Abt für Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Universitatsklinikum Tuebingen
    Onkologie 26:48-53. 2003
  7. ncbi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
    C Bokemeyer
    Universitaetsklinikum Tuebingen, Medizinische Klinik Abteilung II, Otfried Mueller St 10, D 72076 Tuebingen, Germany
    Eur J Cancer 40:2201-16. 2004
  8. pmc Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Br J Cancer 91:683-7. 2004
  9. ncbi Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen, Tuebingen
    J Clin Oncol 19:3029-36. 2001
  10. pmc Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer
    C Bokemeyer
    Department of Haematology Oncology, University of Tuebingen Medical Centre, Otfried Muller Strasse 10, 72076 Tuebingen, Germany
    Br J Cancer 87:1066-71. 2002

Collaborators

Detail Information

Publications120 found, 100 shown here

  1. pmc Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Haematology Oncology, University of Tuebingen Medical Center, Germany
    Br J Cancer 87:729-32. 2002
    ..Irinotecan at a dose of 300-350 mg m(-2) every 3 weeks appears to have no antitumour activity in patients with cisplatin-refractory germ cell cancer and, thus, further investigation in this disease is not justified...
  2. pmc Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
    S Koch
    Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, , , Tuebingen 72076, Germany
    Br J Cancer 89:2133-9. 2003
    ....
  3. pmc Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen Medical Center, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Br J Cancer 86:506-11. 2002
    ..It may also be a valuable addition to the prognostic model particularly in the good and intermediate group for further selection of patients who will profit from high-dose chemotherapy...
  4. ncbi Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy
    C Bokemeyer
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 25:32-9. 2002
    ....
  5. ncbi Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis
    Carsten Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    J Clin Oncol 20:1864-73. 2002
    ..To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies...
  6. ncbi [Chemotherapy of advanced colorectal carcinoma: treatment options for elderly patients]
    C Bokemeyer
    Abt für Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Universitatsklinikum Tuebingen
    Onkologie 26:48-53. 2003
    ..Future trials need to further redefine treatment strategies in elderly patients with colorectal cancer...
  7. ncbi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
    C Bokemeyer
    Universitaetsklinikum Tuebingen, Medizinische Klinik Abteilung II, Otfried Mueller St 10, D 72076 Tuebingen, Germany
    Eur J Cancer 40:2201-16. 2004
    ..Additional trials are warranted, especially on the issues of iron replacement and cost-effectiveness of erythropoietic protein therapy, as well as on tumour response/progression and survival...
  8. pmc Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Br J Cancer 91:683-7. 2004
    ..In conclusion, carboplatin single agent therapy cannot be recommended as standard treatment for any patient subgroup with advanced metastatic seminoma and cisplatin-based combination regimens remain the standard of care...
  9. ncbi Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen, Tuebingen
    J Clin Oncol 19:3029-36. 2001
    ..This study analyzed the presence and the clinical importance of contaminating tumor cells in PBSC preparations used to support HD-Ctx in GCT patients...
  10. pmc Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer
    C Bokemeyer
    Department of Haematology Oncology, University of Tuebingen Medical Centre, Otfried Muller Strasse 10, 72076 Tuebingen, Germany
    Br J Cancer 87:1066-71. 2002
    ..Despite the frequent use of red blood cell transfusions, median haemoglobin nadirs remained about 7.5-8 g dl(-1) during therapy. A correlation of haemoglobin-values after completion of therapy to overall treatment outcome was found...
  11. ncbi Extragonadal germ cell tumors: relation to testicular neoplasia and management options
    Carsten Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    APMIS 111:49-59; discussion 59-63. 2003
    ..Patients with mediastinal nonseminomas have a five-years survival rate of 45%. This outcome is clearly inferior compared to patients with nonseminomatous retroperitoneal primaries who have a five-year survival rate of 62%...
  12. ncbi Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer
    C Bokemeyer
    Department of Hematology Oncology, Internal Medicine II, Eberhard Karls University, Tubingen, Germany
    J Clin Oncol 17:512-6. 1999
    ..This phase II study evaluates the use of gemcitabine in patients with intensively pretreated or cisplatin-refractory testicular germ cell cancers...
  13. ncbi Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG)
    C Bokemeyer
    Department of Internal Medicine, University of Tuebingen Medical Center, Germany
    Int J Cancer 83:848-51. 1999
    ..Future trials combining new active agents may examine alternating treatment strategies in patients with poor-prognostic disease or as salvage treatment...
  14. ncbi Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer
    J Wierecky
    Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, University of Tuebingen Medical Center, Otfried Mueller Strasse 10, 72076 Tuebingen, Germany
    J Cancer Res Clin Oncol 131:255-60. 2005
    ..We investigated the incidence of secondary leukemia in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced testicular cancer...
  15. pmc A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
    Br J Cancer 83:458-62. 2000
    ..While the overall acceptable toxicity allows its use in the palliative setting, it may also be an attractive option to be tested for neoadjuvant or adjuvant treatment...
  16. ncbi Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer S
    H J Schmoll
    Department of Hematology Oncology, University of Halle, Halle, Germany
    J Clin Oncol 21:4083-91. 2003
    ..This analysis reports toxicity and long-term results of a large phase I/II study of sequential high-dose etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced germ cell tumors...
  17. ncbi Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    J Clin Oncol 19:1641-8. 2001
    ....
  18. pmc First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial
    C Bokemeyer
    Tuebingen University Medical Center II, Department of Hematology, Oncology, Rheumatology and Immunology, Eberhard Karls University, Otfried Mueller Str 10, 70276 Tuebingen, Germany
    Br J Cancer 89:29-35. 2003
    ..Compared to data of an international database analysis including 253 patients with mediastinal nonseminoma treated with conventional chemotherapy, the results may indicate that HD-VIP results in an approximately 15% survival improvement...
  19. ncbi Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO
    C Kollmannsberger
    Department of Hematology Oncology, Department of Radiation Oncology, University of Tuebingen, Tuebingen
    Ann Oncol 16:1326-33. 2005
    ..The current two studies evaluate the feasibility, toxicity and efficacy of an adjuvant combined modality treatment strategy containing a three to four-drug chemotherapy regimen plus 5-fluorouracil (FU)-based radiochemotherapy...
  20. ncbi Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen, Germany
    Eur J Cancer 39:775-82. 2003
    ..If feasible, complete surgical resection of residual tumours appears to be the most efficient treatment...
  21. ncbi Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome
    C Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    Cancer 91:1394-401. 2001
    ..Primary radiotherapy seems to be associated with a significantly higher rate of disease recurrence, although most patients will be salvaged by subsequent chemotherapy...
  22. ncbi Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
    J Clin Oncol 20:2031-7. 2002
    ..To investigate the efficacy and toxicity of oxaliplatin, a diaminocyclohaxane platinum derivative with incomplete cross-resistance to cisplatin in patients with relapsed or cisplatin-refractory germ cell cancer...
  23. doi Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy
    K Oechsle
    Department of Oncology, University Medical Center Eppendorf, Hamburg, Germany
    Eur J Cancer 44:1663-9. 2008
    ..Retrospective analysis of characteristics and outcome of germ cell tumour (GCT) patients with cerebral metastases (CM) undergoing high-dose chemotherapy (HD-CTX) or relapsing with CM...
  24. ncbi Treatment of brain metastases in patients with testicular cancer
    C Bokemeyer
    Department of Hematology Oncology, Hannover University Medical School, Germany
    J Clin Oncol 15:1449-54. 1997
    ..This report summarizes the long-term results in 44 patients with brain metastases from testicular cancer treated between 1978 and 1995 at Hannover University Medical School...
  25. ncbi Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma
    J T Hartmann
    Department of Hematology, Oncology and Immunology, Eberhard Karls University, UKT Medical Center II, Tubingen, Germany
    Anticancer Res 20:1177-82. 2000
    ..Mitomycin C has some single-agent activity in advanced gastric cancer but no substantial efficacy was seen as in heavily pretreated colorectal carcinoma...
  26. ncbi Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer
    J T Hartmann
    Department of Hematology Oncology Immunology, Eberhard Karls University Medical Center II, Tubingen, Germany
    Anticancer Drugs 10:729-33. 1999
    ..Mitomycin C demonstrates single-agent activity in pretreated gastric cancer, but has only limited efficacy following cisplatin/paclitaxel-based first-line chemotherapy...
  27. ncbi Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Ann Oncol 13:1017-28. 2002
    ..This investigation evaluates prognostic variables in patients with seminomatous and non-seminomatous extragonadal germ-cell tumors (EGCT) in order to identify relevant factors for long-term outcome following cisplatin-based chemotherapy...
  28. ncbi A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen, Germany
    Ann Oncol 17:1007-13. 2006
    ..Paclitaxel and EGFR inhibitors have additive antitumour effects in vitro. This phase I study assessed the tolerability, pharmacokinetics and efficacy of the combination of matuzumab and paclitaxel in patients with advanced NSCLC...
  29. ncbi Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer
    F Honecker
    Department of Hematology Oncology, University of Tübingen Medical Center, 72076 Tubingen, Germany
    Anticancer Drugs 13:497-503. 2002
    ..Other organ toxicities apart from a slightly higher incidence of peripheral neuropathy were comparable between the two treatment protocols. Efficacy with a response rate of 50% was well preserved by this weekly regimen...
  30. ncbi Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen Medical Center, Otfried Mueller Strasse 10, 72076 Tuebingen, Germany
    J Clin Oncol 22:108-14. 2004
    ..This study investigates the activity of a gemcitabine plus oxaliplatin regimen in these patients...
  31. ncbi [Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?]
    F Honecker
    Abteilunh Hämatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Tubingen
    Onkologie 24:87-94. 2001
    ..Further clinical trials of chemotherapy in elderly patients with colorectal cancer are necessary to gain information about treatment recommendations...
  32. ncbi Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma
    H Dittmann
    Department of Nuclear Medicine, University of Tuebingen, Tuebingen, Germany
    Oncol Rep 8:1393-9. 2001
    ..In patients with suspected relapse of HD, FDG-PET seems not to offer any information over CT scans. Using SUVs is not superior to visual assessment of PET alone...
  33. ncbi Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC)
    F Honecker
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 27:583-8. 2004
    ..A review of the most important trials, assessing treatment options in elderly patients with lung cancer, either prospectively or retrospectively, is provided, and still unresolved issues are addressed...
  34. ncbi Anaemia in cancer patients: pathophysiology, incidence and treatment
    C Bokemeyer
    Department of Oncology, Haematology, Bone Marrow, Transplantation and Pneumology, University of Eppendorf Medical Center, Hamburg, Germany
    Eur J Clin Invest 35:26-31. 2005
    ..Finally, differences in treatment approaches between these erythropoietic proteins are discussed in order to guide treatment decisions specific for the individual patients' situation...
  35. ncbi Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide
    J T Hartmann
    Department of Hematology, Oncology, Immunology, UKT Medical Center II, University of Tubingen, Germany
    Anticancer Res 20:3767-73. 2000
    ..In the light of the long-term consequences of persistent renal damage prevention of nephrotoxicity should be further improved...
  36. ncbi The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors
    J T Hartmann
    Department of Hematology and Oncology, UKT Medical Center II, Eberhard Karls University, Tubingen, Germany
    Anticancer Drugs 11:1-6. 2000
    ..This dose of amifostine may be sufficient for nephroprotection in patients without pre-existing risk factors for renal damage who undergo a restricted number of chemotherapy cycles...
  37. ncbi Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer
    C Kollmannsberger
    Department of Internal Medicine, University of Tuebingen Medical Center, Tuebingen, Germany
    Cancer 95:301-8. 2002
    ....
  38. ncbi Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels
    M Horstmann
    Department of Urology, Eberhard Karls University Tubingen, Hoppe Seyler Str 3, 72076, Tubingen, Germany
    J Cancer Res Clin Oncol 131:715-22. 2005
    ..The value of bFGF serum levels as indicators of systemic tumour dissemination remains to be determined...
  39. pmc Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
    J T Hartmann
    Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tuebingen, Germany
    Br J Cancer 89:2051-6. 2003
    ..In gastric cancer,MMC plus infusional 5-FU/folinic acid may be a potential second-line regimen with promising antitumour activity...
  40. doi Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    C Bokemeyer
    Department of Oncology, Hematology, BMT With Section Pneumology, University Hospital, Hamburg Eppendorf, Germany
    Ann Oncol 22:1535-46. 2011
    ....
  41. doi A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
    J T Hartmann
    Department of Hematology Oncology, University Hospital Schleswig Holstein, Christian Albrechts University Cancer Center North, Arnold Heller Strasse 3, 24105, Kiel, Germany
    Invest New Drugs 31:661-8. 2013
    ..Matuzumab combined with paclitaxel was generally well tolerated in patients with advanced NSCLC. There was some evidence of anticancer activity in relation to the matuzumab 800 mg weekly dose...
  42. ncbi Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors
    F Mayer
    Department of Oncology, Hematology, Immunology and Rheumatology, University of Tübingen Medical Center, Tubingen, Germany
    Ann Oncol 14:825-32. 2003
    ..Even though no uniform pattern of relevant resistance factors has been identified in patients suffering from refractory disease, a significant number of these cases may be caused by defects in the DNA mismatch repair pathway...
  43. ncbi An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
    J T Hartmann
    Department of Medical Oncology, Hematology, Immunology, Rheumatology, Pneumology, South West German Cancer Center, Eberhard Karls University, Tuebingen, Germany
    Invest New Drugs 24:249-53. 2006
    ..The aim of this trial was to evaluate the efficacy of gemcitabine in this setting...
  44. ncbi Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy
    C Kollmannsberger
    Department of Medicine II, University of Tuebingen, Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany
    World J Urol 19:120-5. 2001
    ..It is hoped that the increase in knowledge of the molecular mechanism of testicular cancer may lead to the development of new therapeutic options...
  45. ncbi Evaluation of long-term toxicity after chemotherapy for testicular cancer
    C Bokemeyer
    Department of Hematology Oncology, Hannover University Medical School, Germany
    J Clin Oncol 14:2923-32. 1996
    ..The influence of therapy and patient characteristics and the relationship between different toxicities are assessed...
  46. ncbi Impact of tumor size on the long-term survival of patients with early stage renal cell cancer
    M Kuczyk
    Department of Urology, Eberhard Karls University, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    World J Urol 23:50-4. 2005
    ..The present study demonstrates the need for multivariate statistical approaches when the latest modification of the TNM classification system is critically evaluated...
  47. ncbi [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial
    M de Wit
    Department of Internal Medicine, University Clinic Hamburg Eppendorf, Berlin, Germany
    Ann Oncol 19:1619-23. 2008
    ....
  48. ncbi European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
    H J Schmoll
    European Germ Cell Cancer Consensus Group, Martin Luther University, Department of Hematology Oncology, Halle, Germany
    Ann Oncol 15:1377-99. 2004
    ..Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception...
  49. doi Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
    K Oechsle
    Division of Oncology, Hematology, Bone Marrow Transplantation and Section Pneumology, University Medical Centre Eppendorf, Hamburg University, Germany
    Ann Oncol 22:2654-60. 2011
    ..The objective of the study was to investigate the activity of sunitinib in a cell line model and subsequently in patients with cisplatin-refractory or multiply relapsed germ cell tumors (GCT)...
  50. pmc The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna
    C Bokemeyer
    Department of Hematology Oncology, Hannover University Medical School, Germany
    Br J Cancer 69:863-7. 1994
    ..These results are most likely transferable to the use of mesna in patients with metastatic testicular cancer...
  51. ncbi Platinum organ toxicity and possible prevention in patients with testicular cancer
    J T Hartmann
    Department of Hematology Oncology Immunology, UKT Medical Center II, Eberhard Karls University, Tuebingen, Germany
    Int J Cancer 83:866-9. 1999
    ..Several strategies have been developed to reduce such side effects. Ongoing trials are investigating the role of the aminothiol amifostine as a nephro- and neuroprotectant...
  52. ncbi Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Anticancer Res 23:1899-901. 2003
    ..The number of cytostatic agents effective in patients with advanced soft tissue sarcoma is limited. Trofosfamide, an alkylating agent, has been shown to be effective in several solid and haematological tumors...
  53. ncbi Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study
    A Jakob
    Department of Hematology Oncology, University Hospital Tubingen, Otfried Mueller Strasse 10, 72076 Tubingen, Germany
    Anticancer Drugs 13:405-10. 2002
    ..It can be safely used in patients who have been intensively pretreated by myelotoxic chemotherapy or who have even relapsed after high-dose chemotherapy with PBSCT...
  54. pmc Long-term effects on sexual function and fertility after treatment of testicular cancer
    J T Hartmann
    Department of Hematology Oncology Immunology Rheumatology, UKL Medical Center II, Eberhard Karls University, , Germany
    Br J Cancer 80:801-7. 1999
    ..Twenty-one of 40 patients were able to fulfil their wish for children, and no congenital abnormalities were observed in these children...
  55. ncbi Therapy-related malignancies following treatment of germ cell cancer
    C Kollmannsberger
    Department of Medicine, University of Tuebingen, Germany
    Int J Cancer 83:860-3. 1999
    ..However, even the acceptably low number of therapy-related leukemias should encourage the search for equally effective but less toxic therapies...
  56. ncbi Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience
    M A Kuczyk
    Department of Urology, Eberhard Karls University, Hoppe Seyler Str 3, 72076 Tubingen, Germany
    World J Urol 22:55-9. 2004
    ..It became evident that in selected cases chemotherapy alone can be considered a curative treatment option...
  57. ncbi Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients
    S Kobold
    1 Department of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, Department of Internal Medicine II, University Cancer Center Hamburg Hubertus Wald Tumorzentrum, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 46:1053-6. 2011
    ..Accordingly, plerixafor seems to be safe and effective in germ cell tumor patients who have failed prior mobilization therapy. Larger prospective studies are warranted to further assess its use in germ cell cancer...
  58. ncbi Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC)
    F Honecker
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 27:500-5. 2004
    ..Further evaluation of these topics is needed, and can be achieved by trials specifically designed for elderly patients or patients with reduced performance status...
  59. ncbi Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine
    U Reichmann
    Department of Radiooncology, University of Tuebingen, Tuebingen, Germany
    Ann Oncol 18:1981-4. 2007
    ..This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients...
  60. pmc Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
    C Seidel
    Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Eppendorf, Martinistrase 52, 20246 Hamburg, Germany
    Br J Cancer 109:2998-3004. 2013
    ..The aim of our analysis is to further characterise the prognostic relevance of early tumour shrinkage (TS) during VEGF-targeted therapy in mRCC, in order to explore whether this could define a group of patients with long-term survivorship...
  61. ncbi [Allogeneic hematopoetic cell transplantation in patients with solid tumors - Contra]
    C Bokemeyer
    Abteilung Hamatologie, Onkologie, Immunologie und Rheumatologie, Universitatsklinikum Tubingen
    Dtsch Med Wochenschr 127:2215. 2002
  62. ncbi A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors
    J T Hartmann
    Department of Hematology and Oncology, UKT Medical Center II, Eberhard Karls University of Tubingen, Germany
    Invest New Drugs 18:281-9. 2000
    ..This may be advantageous if repetitive cycles of chemotherapy or subsequent administration of high dose chemotherapy is planned...
  63. ncbi Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors
    C Bokemeyer
    Eberhard Karls Universitat Tubingen, Medizinische Klinik und Poliklinik, Deutschland
    Oncology 55:177-88. 1998
    ....
  64. ncbi [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker]
    A C Pfannenberg
    Abteilung für Radiologische Diagnostik, Eberhard Karls Universität Tuebingen
    Rofo 176:76-84. 2004
    ..To assess the ability of [(18)F]FDG-PET, CT/MRI and serum tumor marker (TM) for the early prediction of response in patients with metastatic germ cell tumors (GCT) undergoing salvage high-dose chemotherapy (HD-CTX)...
  65. doi Evaluation of BM cytomorphology after allo-SCT in patients with AML
    M Christopeit
    Department of Internal Medicine, Oncology and Haematology, University Hospital Halle Saale, Halle Saale, Germany
    Bone Marrow Transplant 47:1538-44. 2012
    ..Thus, in the cohort studied, BM cellularity represents a prognostic parameter for the post-transplant period in AML patients. Dysplasia seems to be an unspecific phenomenon in the cohort analysed...
  66. ncbi [Compression syndromes]
    J Wierecky
    Abteilung für Hämatologie, Onkologie, Immunologie und Rheumatologie, Medizinische Klinik II, Universitatsklinikum Tubingen
    Internist (Berl) 46:9-18. 2005
    ..MRI should be preferred in the diagnostic work-up, corticosteroids be administered promptly after biopsy. Radiation therapy or surgical treatment should be started as soon as possible...
  67. doi European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:478-96. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands...
  68. doi Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO)
    Jorg Thomas Hartmann
    Abteilung Onkologie Hämatologie Immunologie Rheumatologie Pulmologie, Südwestdeutsches Tumorzentrum Comprehensive Cancer Center Tübingen, Eberhard Karls Universitat Tubingen, Germany
    Onkologie 31:237-41. 2008
    ..The aim of the study was to establish the recommended dose and to evaluate the safety of gefitinib plus FUFOX regimen in irinotecan-refractory colorectal carcinoma (CRC)...
  69. ncbi Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines
    Michael Heuser
    Department of Hematology, Hemostaseology, and Oncology, Hannover Medical School, Hannover, Germany
    Semin Hematol 44:148-56. 2007
    ..Strategies are being developed to tailor the use of CSFs to patients with a high risk of adverse outcome of FN...
  70. ncbi The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas
    Eva M Murga Penas
    University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Haematologica 92:405-9. 2007
    ..FISH revealed the involvement of the immunoglobulin locus in the t(11;14;18). Rapid amplification of cDNA ends (RACE)-PCR to detect the involved partner gene on 6q showed exclusively wild-type API2 and MALT1 sequences...
  71. doi Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Stuttgart, Stuttgart, Germany
    J Clin Oncol 26:2131-8. 2008
    ....
  72. ncbi Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group
    Anja Lorch
    Department of Hematology, Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany
    J Clin Oncol 25:2778-84. 2007
    ..To compare single versus sequential high-dose chemotherapy (HDCT) as first or subsequent salvage treatment in patients with relapsed or refractory germ cell tumors (GCTs)...
  73. ncbi Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
    Christian Peschel
    Technische Universitat, III Medizinische Klinik, Munchen, Germany
    Lung Cancer 60:374-80. 2008
    ..v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC)...
  74. ncbi Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors
    Sandra Mueller
    Department of Oncology, Hematology, Immunology and Rheumatology, Medical Center, University of Tuebingen, Tuebingen, Germany
    Invest New Drugs 25:519-24. 2007
    ..However, possibly in view of their extensive telomere "reserve," telomerase inhibition did neither result in increased sensitivity of 2102 EP cells to cisplatin nor did co-treated cells show accelerated telomere shortening...
  75. ncbi Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study
    Jorg Thomas Hartmann
    Abteilung Onkologie Hämatologie Immunologie Rheumatologie Pulmologie, Medizinische Klinik II, Eberhard Karls Universitat, Tubingen, Germany
    Onkologie 30:235-40. 2007
    ..To assess the toxicity and activity of bolus mitomycin C (MMC) in combination with a 24-hour continuous infusion of 5-fluorouracil (5-FU) in gastric cancer patients who had received at least one prior chemotherapy regimen...
  76. ncbi A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC)
    Eckart Laack
    University Hospital Hamburg Eppendorf, Hamburg, Germany
    Lung Cancer 57:181-6. 2007
    ..The aim of this phase II trial was to evaluate the efficacy and safety of a combination chemotherapy containing irinotecan (CPT-11) and carboplatin as first-line treatment of patients with small cell lung cancer (SCLC)...
  77. ncbi Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer
    Stefan Welz
    Heinrich Heine University of Dusseldorf, Dusseldorf, Germany
    Int J Radiat Oncol Biol Phys 69:1429-35. 2007
    ..On the basis of previously reported results of a Phase II trial using a more aggressive, cisplatin-containing chemoradiotherapy schedule, we investigated the effects of this approach on long-term renal function...
  78. ncbi A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer
    Christof Burkart
    Departments of Medical Oncology, Hematology, Immunology, Rheumatology, Pulmology, Medical Center II, Tubingen, Germany
    Anticancer Res 27:2845-8. 2007
    ..This study investigated the efficacy and toxicity of weekly single-agent irinotecan in patients with metastatic disease relapsing after cisplatin-based chemotherapy...
  79. doi A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
    Michael Gorn
    Department of Oncology, Hematology, Bone Marrow Transplantation with the Section of Pneumology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Onkologie 31:185-9. 2008
    ..The aim of this pilot study was to evaluate the efficacy and safety of a chemotherapy containing docetaxel and oral trofosfamide as a 'metronomic' secondline treatment of patients with metastatic non-small cell lung cancer (NSCLC)...
  80. doi Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer
    Christian Kollmannsberger
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia Vancouver Cancer Centre, Vancouver, British Columbia, Canada
    Curr Opin Support Palliat Care 2:167-72. 2008
    ..This review summarizes the existing evidence including several recently published larger studies on the use of high-dose chemotherapy in these patients...
  81. doi Platinum-based chemotherapy plus cetuximab in head and neck cancer
    Jan B Vermorken
    Antwerp University Hospital, Department of Medical Oncology, Edegem, Belgium
    N Engl J Med 359:1116-27. 2008
    ..We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck...
  82. doi European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:497-513. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands...
  83. ncbi Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group
    Jorg T Hartmann
    Department of Oncology, South West German Comprehensive Cancer Center, Eberhard Karls University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    J Clin Oncol 25:5742-7. 2007
    ....
  84. doi Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
    Salah Eddin Al-Batran
    Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt, Germany
    J Clin Oncol 26:1435-42. 2008
    ..This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer...
  85. ncbi Germ-cell tumors
    Anja Lorch
    N Engl J Med 357:1772-3; author reply 1773-4. 2007
  86. doi Erythropoietins should be used according to guidelines
    Matti S Aapro
    Lancet Oncol 9:412-3. 2008
  87. doi Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
    ..This randomised trial assessed whether six or eight cycles of R-CHOP-14 can improve outcome of these patients compared with six or eight cycles of CHOP-14...
  88. ncbi Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?
    Carsten Bokemeyer
    J Clin Oncol 26:1783-5. 2008
  89. ncbi Lectin histochemistry of metastatic adenocarcinomas of the lung
    Ina Thom
    Department of Hematology, Oncology and Pneumology, University Hospital Hamburg Eppendorf, Germany
    Lung Cancer 56:391-7. 2007
    ..The aim of the present investigation was thus to analyse a possible association between the presence of lectin binding sites of pulmonary adenocarcinoma cells and their lymph node and haematogenous metastatic cells...
  90. ncbi An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors
    Karin Oechsle
    Department of Oncology Hematology Bone marrow transplantation Pneumology, University Medical Center, Eppendort, Hamburg, Germany
    Anticancer Drugs 18:273-6. 2007
    ..Capecitabine was well tolerated, but is not effective in heavily pretreated patients with cisplatin-refractory or relapsed germ cell tumors...
  91. ncbi Anemia impact and management: focus on patient needs and the use of erythropoietic agents
    Carsten Bokemeyer
    Universitatsklinikum Tuebingen, Medizinische Klinik Abteilung, Germany
    Semin Oncol 31:4-11. 2004
    ..There is a strong need for increased awareness of cancer-related anemia and the consequences of its lack of treatment...
  92. ncbi Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil
    Joerg Thomas Hartmann
    Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tubingen, Germany Krankenhaus Nordwest, Frankfurt, Germany
    Anticancer Drugs 15:473-7. 2004
    ..Elderly patients had the same probability to respond...
  93. ncbi 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial
    Maria De Santis
    Department of Medical Oncology, Kaiser Franz Josef Spital, Kundratstrasse 3, A 1100 Wien, Austria
    J Clin Oncol 22:1034-9. 2004
    ..To define the clinical value of 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG PET) as a predictor for viable residual tumor in postchemotherapy seminoma residuals in a prospective multicentric trial...
  94. ncbi Is once-weekly epoetin beta 'highly effective' in treating anaemia in patients with lymphoproliferative malignancy?
    Carsten Bokemeyer
    Br J Haematol 125:98-9; author reply 99-100. 2004
  95. ncbi The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management
    Anna C Pfannenberg
    Department of Diagnostic Radiology, Eberhard Karls University Tuebingen, Hoppe Seyler Strasse 3, 72076 Tuebingen, Germany
    World J Urol 22:132-9. 2004
    ..PET seems useful in patients with stable disease or partial remission in CT/MRI and normalized TM as well as in marker-negative disease...
  96. ncbi Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma
    Christian Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen, Tuebingen, Germany
    Cancer 94:2353-62. 2002
    ....
  97. ncbi Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment
    Frank Mayer
    Pathology Laboratory for Exp Patho Oncology, University Hospital Rotterdam Daniel, Josephine Nefkens Institute, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands
    Cancer Res 62:2758-60. 2002
    ..001). In 5 of all 11 unstable tumors, MSI correlated with immunohistochemical findings. This study demonstrates for the first time a positive correlation between MSI and treatment resistance in GCT...
  98. ncbi Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer
    Silas C Martin
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, USA
    Pharmacoeconomics 21:1153-69. 2003
    ..Although the study was not designed or powered to evaluate survival, a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126])...
  99. ncbi Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia
    Tim H Brummendorf
    Blood 101:375-6. 2003
  100. ncbi Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors
    Friedemann Honecker
    Department of Pathology, Laboratory for Experimental Patho Oncology, Josephine Nefkens Institute, Erasmus MC, University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Lab Invest 83:1489-95. 2003
    ..We therefore conclude that XPA does not play a critical role in overall treatment resistance of GCTs...
  101. ncbi Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia
    Tim H Brummendorf
    Abteilung Hämatologie Onkologie, Medizinische Universitatsklinik, Tubingen, Germany
    Ann N Y Acad Sci 996:26-38. 2003
    ..05), interphase FISH (n = 204, p = 0.002), or quantitative RT-PCR (n = 371, p < 0.05). In conclusion, the increase in telomere length under treatment with imatinib reflects a shift from Ph+ to Ph- cells in the PB of patients with CML...